# Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia

> **NCT00723346** · PHASE1,PHASE2 · COMPLETED · sponsor: **ERYtech Pharma** · enrollment: 25 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **BIOLOGICAL:** GRASPA
- **BIOLOGICAL:** GRASPA
- **BIOLOGICAL:** GRASPA
- **DRUG:** native L asparaginase

## Key facts

- **NCT ID:** NCT00723346
- **Lead sponsor:** ERYtech Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-08
- **Final completion:** 2009-03
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2012-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00723346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00723346, "Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00723346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*